×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Doer Biologics announces the dosing of the first patient in a Phase 2 study of DR10624 for severe hypertriglyceridemia treatment.
Mediar Therapeutics launches a second clinical program targeting fibrosis with novel first-in-class antibodies
07 Aug 2024
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of
...
Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans
Mytos announces partnerships with StemSight, Rinri Therapeutics, and Novadip to drive next-generation cell therapy trials
Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.
CRENESSITY® lowers glucocorticoid doses while maintaining androgen control in adults with classic congenital adrenal hyperplasia
SHARx’s Paul Pruitt Warns That Patent Expiration Does Not Guarantee Immediate Savings
By
SHARx
SHARx
16 Nov 2026
Seawolf Therapeutics Launches With $100 Million to Advance DNA-Based Therapies
By
Seawolf Therapeutics
Seawolf Therapeutics
16 Nov 2026
Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data at ASH 2026, Demonstrating Promising Leukemia Treatment Results
By
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc.
16 Nov 2026
Bruker Announces the Appointment of Institute Director, Biopharma Entrepreneur, and Immunology Leader Dr. Eicke Latz to Its Board of Directors
By
Bruker Corporation
Bruker Corporation
16 Nov 2026
CS Analytical to Offer Testing Services for Sunscreen Ingredients Used in Pharmaceutical and Cosmetic Products
By
CS Analytical
CS Analytical
13 Nov 2026
VectorY Therapeutics Raises €74.5 Million to Advance Neurodegenerative Disease Pipeline
By
VectorY Therapeutics
VectorY Therapeutics
11 Nov 2026
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
FDA Updates WINREVAIR™ Label with HYPERION Phase 3 Trial Data in Adults Newly Diagnosed with PAH
By
Merck & Co., Inc.
Sep 22
Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate
By
PHC Corporation
Mar 20
Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care
By
Superpower
Nov 02
November
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe to Our Monthly Newsletter
Subscribe to Pharmaceutical Era’s monthly newsletter,
Pharmaceutical Leaders Digest
®, to receive timely updates from across the pharmaceutical industry.
I agree with the
Terms and conditions
×
and the
Privacy policy
×
Please enable the javascript to submit this form
Subscribe
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand